N/A N=120 Endometrial Injury for Unexplained Infertility
Infertility
Primary: Measurement of Uterine Artery Pulsatility Index — 2.40; 2.35 index — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=662 Endometrial Safety Study
Postmenopause
Primary: Number of Participants in the DRSP/E2 Group With an Assessment of Endometrial Hyperplasia or Worse at End of Study (EoS) (1 Year of Treatment) — 0 Participants
N/A N=118 Endometrial Injury and Single Embryo Transfer
Primary Infertility
Primary: Clinical Pregnancy Rate
N/A N=100 Adipocytokines in Endometrial Cancer
Endometrial Cancer · Obesity
Primary: Correlation Between Circulating Levels of These Markers and Demographic Characteristics. — 39; 42; 11; 8 Participants — p=0.026
Phase 3 N=349 Does Endometrial Injury Improve Intrauterine Insemination Outcome?
Infertility
Primary: Chemical Pregnancy Rate — 40; 19 participants
Phase 2 N=41 Assessing the Endometrial Environment in Recurrent Pregnancy Loss and Unexplained Infertility
Recurrent Pregnancy Loss · Unexplained Infertility
Primary: Abnormal Microbiome Bacterial Sequencing
Phase 2 N=30 Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
Atypical Endometrial Hyperplasia · Endometrial Carcinoma
Primary: Best Pathologic Responses — 17; 4; 6; 1 participants
Phase 2 N=20 Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients
Complex Atypical Hyperplasia · Endometrial Cancer
Primary: Complete Response Rate - 6 Months — 80 percentage of participants
N/A N=204 Lymph Node Mapping in Patients With Endometrial Cancer
Endometrial Cancer
Primary: Negative Predictive Value of Sentinel Lymph Node Prediction of Metastatic Disease — 98.8 percentage of patients
Phase 2 N=75 Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation
Primary: Histologic Response in Endometrial Adenocarcinomas of the Uterine Corpus That Are Progesterone Receptor Positive Compared With Those That Are Progesterone Receptor…
N/A N=56 Enriched Environments in Endometriosis
Endometriosis-related Pain · Endometriosis · Pelvic Pain
Primary: Pain Perception — 7.0; 6.2; 7.2; 5.1 units on a scale
N/A N=300 Endometriosis and the Appendix - Incidence and Pathologic Analysis
Endometriosis of the Appendix
Primary: Incidence of Endometriosis of the Appendix — 23; 30 Participants — p=0.01
N/A N=43 Letrozole as a Treatment of Endometrial Cancer
Endometrial Carcinoma
Primary: Changes in Ki67 Expression After About 3 Weeks of Letrozole Treatment for Patients With Endometrial Cancer — -3.75; 1.583 percentage of Ki67 staining cells — p=0.0373
N/A N=70 Endometrial Biopsy Instrument Comparison Study
Pain
Primary: Compare Pipelle and Explora Curette Groups With Respect to Patient Perception of Pain Associated With the Procedure as Rated by a 100mm Visual Analog Scale (VAS)…
Phase 2 N=150 Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma
Endometrial Atypical Hyperplasia · Endometrial Adenocarcinoma
Primary: Cumulative CR Rates Within 16 Weeks — 23; 12 Participants
Phase 2 N=31 Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Recurrent Endometrial Carcinoma
Primary: Percentage of Patients With Progression-free Survival > 6 Months — 10 percentage of participants
Phase 4 N=1 Ulipristal for Endometriosis-related Pelvic Pain
Endometriosis
Primary: Pelvic Pain — 3.5; 0.2; 3.9 units on a scale — p=<0.05
N/A N=167 A Comparison of Narrow Band Imaging (NBI) and Standard White Light Laparoscopy to Detect Endometriosis
Endometriosis
Primary: Diagnostic Yield — 81; 25 participants
Phase 2 N=141 Comparison of Different Doses of Oestrogen Therapy for Preventing Intrauterine Adhesion
Asherman Syndrome
Primary: the AFS Score at Second-look Hysteroscopy — 1.6; 1.9 units on a scale — p=>0.05
Phase 4 N=24 Clinical Trial Comparing Endometrial Transformation With Subcutaneous Progesterone Versus Intramuscular Progesterone
Reproductive Techniques, Assisted
Primary: Predecidual Transformation — 1; 2; 7; 8 participants — p=0.3395
Phase 2 N=35 Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.
Endometrial Carcinoma
Primary: Determination (for ITT (Intet-to-Treat Set): Efficacy of a Monthly Administration of Fulvestrant in Patients With Recurrent or Metastatic Endometrial Carcinoma by…
Phase 2 N=8 Evaluation of Endometriosis With 18F-fluoroestradiol PET / MRI
Endometriosis
Primary: Sensitivity of FES PET/MRI for Evaluating Endometriosis (Percentage of Positive Scans) — 67 percentage of positive scans — p=0.317
Phase 2 N=67 Quinagolide Vaginal Ring on Lesion Reduction Assessed by MRI in Women With Endometriosis/Adenomyosis
Endometriosis
Primary: Changes in the Sizes (mm) of Endometrioma, Deep Infiltrating Endometriosis (DIE) and Adenomyosis Lesions Summed by Type on Magnetic Resonance (MR) Images at Cycle 4…
N/A N=120 RCT(Randomized Clinical Trial ) of Antibiotic Therapy in Chronic Endometritis
Chronic Endometritis
Primary: The Conversion Rate of CE (From Positive to Negative) — 89.8; 12.7 Percentage of participants
Phase 1 N=10 MK-3475 Immunotherapy in Endometrial Carcinoma
Endometrial Cancer · Endometrial Carcinoma · Neoplasms, Endometrial
Primary: Safety as Measured by Any Grade Treatment Related Adverse Events Experienced by ≥ 2 Patients — 10; 9; 8; 8 Participants
Phase 4 N=37 Endometrial Markers and Response of Endometriosis Patients to Prolonged GnRH Agonist Prior to IVF
Endometriosis · Infertility
Primary: Patients Who Responded to Controlled Ovarian Hyperstimulation — 7; 5; 3; 5 Participants
Phase 2 N=10 A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women
Adenocarcinoma of the Endometrium
Primary: IHC-based Tissue Markers of Proliferation
N/A N=104 Quality of Life in Premenopausal Women With Heavy Menstrual Bleeding
Heavy Menstrual Bleeding
Primary: Hot Flush Frequency Total Score (HFRS) Change — 9.3; 8.8; 12.7 score on a scale
Phase 2 N=40 Exemestane in Treating Patients With Complex Atypical Hyperplasia of the Endometrium/Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer
Atypical Hyperplasia · Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia · Endometrial Carcinoma
Primary: Change in Tumor Proliferation — -0.17 percent (represented by mean) of cells
Early Phase 1 N=50 Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma · FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma · FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma
Primary: Mean Post-treatment Tumor Progesterone Receptor H-score (Histology Score) — 53.6; 42.7 units on a scale — p=0.87